Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Poly-Arginine Peptides Reduce Infarct Volume In A Permanent Middle Cerebral Artery Rat Stroke Model, D Milani, V Clark, J Cross, R Anderton, N Knuckey, B Meloni
Poly-Arginine Peptides Reduce Infarct Volume In A Permanent Middle Cerebral Artery Rat Stroke Model, D Milani, V Clark, J Cross, R Anderton, N Knuckey, B Meloni
Medical Papers and Journal Articles
Background: We recently reported that poly-arginine peptides have neuroprotective properties both in vitro and in vivo. In cultured cortical neurons exposed to glutamic acid excitotoxicity, we demonstrated that neuroprotective potency increases with polymer length plateauing at R15 to R18 (R = arginine resides). In an in vivo study in rats, we also demonstrated that R9D (R9 peptide synthesised with D-isoform amino acids) administered intravenously at a dose of 1000 nmol/kg 30 min after permanent middle cerebral artery occlusion (MCAO) reduces infarct volume. Based on these positive in vitro and in vivo findings, we decided to examine the neuroprotective efficacy of …
The R18 Polyarginine Peptide Is More Effective Than The Tat-Nr2b9c (Na-1) Peptide When Administered 60 Minutes After Permanent Middle Cerebral Artery Occlusion In The Rat, D Milani, N Knuckey, R Anderton, J Cross, B Meloni
The R18 Polyarginine Peptide Is More Effective Than The Tat-Nr2b9c (Na-1) Peptide When Administered 60 Minutes After Permanent Middle Cerebral Artery Occlusion In The Rat, D Milani, N Knuckey, R Anderton, J Cross, B Meloni
Medical Papers and Journal Articles
We examined the dose responsiveness of polyarginine R18 (100, 300, and 1000 nmol/kg) when administered 60 minutes after permanent middle cerebral artery occlusion (MCAO).The TAT-NR2B9c peptide, which is known to be neuroprotective in rodent and nonhuman primate stroke models, served as a positive control. At 24 hours afterMCAO, there was reduced total infarct volume in R18 treated animals at all doses, but this reduction only reached statistical significance at doses of 100 and 1000 nmol/kg. The TAT-NR2B9c peptide reduced infarct volume at doses of 300 and 1000 nmol/kg, but not to a statistically significant extent, while the 100 nmol/kg dose …